Related Experiment Video
Updated: Feb 28, 2026
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Effects of Levosimendan on Patients with Heart Failure Complicating Acute Coronary Syndrome: A Meta-Analysis of
Guokai Shang1, Xinyan Yang1, Daijun Song2
1The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Department of Cardiology, Qilu Hospital of Shandong University, #107 West Wenhua Road, Ji'nan, 250012, People's Republic of China.
Insights
Levosimendan shows promise in reducing mortality and worsening heart failure (HF) for patients with acute coronary syndrome (ACS). This drug offers hemodynamic benefits but carries a risk of hypotension.
Area of Science:
- Cardiology
- Pharmacology
- Critical Care Medicine
Background:
- Prognosis for heart failure (HF) and cardiogenic shock (CS) complicating acute coronary syndrome (ACS) is poor.
- Identifying effective treatments for HF/CS-ACS is crucial.
Purpose of the Study:
- To evaluate the clinical outcomes of levosimendan in patients with HF/CS complicating ACS.
- To synthesize evidence from randomized controlled trials on levosimendan's efficacy and safety.
Main Methods:
- Systematic literature search of PubMed, EMBASE, and Cochrane Library.
- Inclusion of nine randomized controlled trials involving 1065 patients.
- Comparative analysis of levosimendan versus control groups.
Main Results:
- Levosimendan significantly reduced total mortality and worsening HF in the overall patient group.
- Reduced mortality was observed in HF-ACS patients, but not in CS-ACS patients.
- Hemodynamic improvements included decreased pulmonary capillary wedge pressure and systemic vascular resistance, with increased cardiac index.
Conclusions:
- Levosimendan is a potential therapeutic option for reducing mortality and worsening HF in HF/CS-ACS patients.
- The drug provides hemodynamic benefits but is associated with an increased risk of hypotension.
- Further research may clarify its role compared to other inotropes like dobutamine.
Background:
The prognosis for patients with heart failure (HF), including cardiogenic shock (CS), complicating acute coronary syndrome (ACS) remains poor.
Objective:
This study aimed to review the relevant literature and evaluate whether levosimendan was associated with better clinical outcomes in these patients.
Methods:
We searched PubMed, EMBASE, and the Cochrane library databases for randomized controlled trials that investigated levosimendan compared with any control in patients with HF/CS complicating ACS.
Results:
A total of 1065 patients from nine trials were included in this study. Analysis showed that levosimendan significantly reduced total mortality and the incidence of worsening HF. In patients with HF-ACS, levosimendan was associated with reduced mortality. In patients with CS-ACS, no significant difference was observed between the two groups. Levosimendan contributed to significantly reduced mortality when compared with placebo, but no significant reduction was seen compared with dobutamine. Compared with controls, levosimendan decreased pulmonary capillary wedge pressure and systemic vascular resistance and increased cardiac index, with no significant difference observed between the groups in terms of heart rate. Levosimendan non-significantly increased the risk of hypotension but did not increase the risk of ischemic episodes, sinus tachycardia, atrial fibrillation, or ventricular arrhythmias.
Conclusion:
Levosimendan appears to be a promising drug to reduce mortality and worsening HF in patients with HF/CS-ACS. It appears to provide hemodynamic benefit and was associated with an increased risk of hypotension.
More Related Videos
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
07:24Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Heart Failure V: Medical Management
01:26Heart Failure Drugs: Inotropic Agents
01:22Heart Failure Drugs: β-Blockers
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:22Heart Failure Drugs: Diuretics